Daejeon just became a medicine-making hub: a €300 million (about $351 million) bioprocessing plant opens

Every modern biologic medicine — the kind grown in living cells — depends on unglamorous essentials: culture media, process liquids, sterile sampling kits. MilliporeSigma, the life-science arm of Merck KGaA, has opened a 44,500-square-metre Asia-Pacific Bioprocessing Production Center in Daejeon, South Korea, an investment of more than €300 million (about $351 million) and the company's largest in the region. From Daejeon it will supply drugmakers across Asia-Pacific from early experiments to full commercial production, shortening supply lines for medicines made in the region. The plant itself was designed to run without on-site fossil fuels, using solar power, heat pumps and reused rainwater. Daejeon's mayor, Tae-Jeong Heo, called its completion a turning point in the city's rise as a global bio hub.

SDG 9 · Industry, innovation and infrastructure — Mechanism: infrastructure build